About Genewity

Genewity B.V. develops autologous thymus tissue using gene-modified induced pluripotent stem cells to restore immune function in patients with congenital athymia and autoimmune disorders. This technology addresses the lack of effective treatments for severe immune deficiencies by creating patient-specific thymic organoids that enhance T-cell development and immune tolerance.

```xml <problem> Patients with congenital athymia and autoimmune disorders lack effective treatments to restore immune function. Current therapies do not address the underlying thymic defects, leading to severe immune deficiencies and limited T-cell development. There is a critical need for patient-specific solutions that can regenerate the thymus and re-establish immune tolerance.</problem> <solution> Genewity B.V. is developing autologous thymus tissue using gene-modified induced pluripotent stem cells (iPSCs) to address immune reconstitution. Their proprietary i-Thymus platform differentiates patient-derived iPSCs into functional thymic organoids, enabling the replacement of thymic function without donor tissue limitations. For autoimmune diseases, Genewity is creating specialized thymus tissue (i-TOL) to restore immune tolerance by inducing apoptosis in auto-reactive T-cells and promoting regulatory T-cell development. This approach aims to switch OFF excessive T-cell immunity and reprogram the patient’s immune system toward a tolerogenic state.</solution> <features> - Autologous cell therapy using patient-derived induced pluripotent stem cells (iPSCs) - Gene modification techniques to direct differentiation of iPSCs into functional thymic organoids - i-Thymus platform for treating congenital athymia by switching ON T-cell immunity - i-TOL platform for treating autoimmune diseases by switching OFF excessive T-cell immunity - Induction of apoptosis in auto-reactive T-cells to restore immune tolerance - Promotion of regulatory T-cell development for immune system reprogramming - Collaboration with world-leading institutions and industry partners for preclinical and clinical research </features> <target_audience> The primary target audience includes patients with congenital athymia and autoimmune disorders, as well as healthcare providers specializing in immunology and gene therapy. </target_audience> ```

What does Genewity do?

Where is Genewity located?

Genewity is based in The Netherlands.

When was Genewity founded?

Genewity was founded in 2022.

Location

The Netherlands

Founded

2022

Employees

14 employees

Major Investors

EIC Accelerator

Looking for specific startups?

Try our free semantic startup search

Genewity

Score: 100/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

genewity.tech 300+

Crunchbase

Founded 2022 – The Netherlands

Funding

Major Investors

EIC Accelerator

Team (10+)

Aline Zbinden

CTO

Company Description

Problem

Patients with congenital athymia and autoimmune disorders lack effective treatments to restore immune function. Current therapies do not address the underlying thymic defects, leading to severe immune deficiencies and limited T-cell development. There is a critical need for patient-specific solutions that can regenerate the thymus and re-establish immune tolerance.

Solution

Genewity B.V. is developing autologous thymus tissue using gene-modified induced pluripotent stem cells (iPSCs) to address immune reconstitution. Their proprietary i-Thymus platform differentiates patient-derived iPSCs into functional thymic organoids, enabling the replacement of thymic function without donor tissue limitations. For autoimmune diseases, Genewity is creating specialized thymus tissue (i-TOL) to restore immune tolerance by inducing apoptosis in auto-reactive T-cells and promoting regulatory T-cell development. This approach aims to switch OFF excessive T-cell immunity and reprogram the patient’s immune system toward a tolerogenic state.

Features

Autologous cell therapy using patient-derived induced pluripotent stem cells (iPSCs)

Gene modification techniques to direct differentiation of iPSCs into functional thymic organoids

i-Thymus platform for treating congenital athymia by switching ON T-cell immunity

i-TOL platform for treating autoimmune diseases by switching OFF excessive T-cell immunity

Induction of apoptosis in auto-reactive T-cells to restore immune tolerance

Promotion of regulatory T-cell development for immune system reprogramming

Collaboration with world-leading institutions and industry partners for preclinical and clinical research

Target Audience

The primary target audience includes patients with congenital athymia and autoimmune disorders, as well as healthcare providers specializing in immunology and gene therapy.